Factor XI Inhibitors for Myocardial Infarction: A Safer Path to Thrombotic Protection?

• References

• 1 Angiolillo DJ, Capodanno D. Uncoupling thrombosis and hemostasis by inhibiting factor XI. N Engl J Med 2025; 392 (04) 400-403
• 2 Greco A, Laudani C, Spagnolo M. et al. Pharmacology and clinical development of factor XI inhibitors. Circulation 2023; 147 (11) 897-913
• 3 Occhipinti G, Laudani C, Spagnolo M. et al. Pharmacological and clinical appraisal of factor XI inhibitor drugs. Eur Heart J Cardiovasc Pharmacother 2024; 10 (03) 245-258
• 4 Rao SV, O'Donoghue ML, Ruel M. et al. ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2025; 151 (13) e771-e862
• 5 Eikelboom JW, Connolly SJ, Bosch J. et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377 (14) 1319-1330
• 6 Wallentin L, Becker RC, Budaj A. et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11) 1045-1057
• 7 Angiolillo DJ, Galli M, Collet JP, Kastrati A, O'Donoghue ML. Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention 2022; 17 (17) e1371-e1396
• 8 De Caterina R, Goto S. Targeting thrombin long-term after an acute coronary syndrome: opportunities and challenges. Vascul Pharmacol 2016; 81: 1-14
• 9 Mega JL, Braunwald E, Wiviott SD. et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366 (01) 9-19
• 10 Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 2006; 27 (05) 519-526
• 11 Morrow DA, Braunwald E, Bonaca MP. et al; TRA 2P–TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366 (15) 1404-1413
• 12 Gibson CM, Bahit MC, Mehran R. et al; Librexia ACS Committees and Investigators.. Oral factor XIa inhibitor milvexian after a recent acute coronary syndrome: rationale and design of the phase 3 (Librexia ACS). Am Heart J 2025; 285: 21-28
• 13 Rao SV, Kirsch B, Bhatt DL. et al; PACIFIC AMI Investigators. A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction. Circulation 2022; 146 (16) 1196-1206
• 14 Piccini JP, Patel MR, Steffel J. et al. Asundexian versus apixaban in patients with atrial fibrillation. N Engl J Med 2024
• 15 Gibson CM. In the wake of oceanic-AF, is equipoise regarding factor XI inhibition still afloat?. J Am Coll Cardiol 2025; 85 (11) 1210-1212
• 16 Vassart J, Didembourg M, Morimont L. et al. Asundexian in atrial fibrillation: can pharmacodynamic data explain the failure?. Thromb Res 2024; 236: 236-239
• 17 Jain SS, Mahaffey KW, Pieper KS. et al; LIBREXIA AF Trial Investigators and Committees. Milvexian vs apixaban for stroke prevention in atrial fibrillation: the LIBREXIA atrial fibrillation trial rationale and design. Am Heart J 2024; 277: 145-158
• 18 Piccini JP, Caso V, Connolly SJ. et al; PACIFIC-AF Investigators. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet 2022; 399 (10333): 1383-1390
• 19 Shoamanesh A, Mundl H, Smith EE. et al; PACIFIC-Stroke Investigators. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet 2022; 400 (10357): 997-1007
• 20 Sharma M, Molina CA, Toyoda K. et al. Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 2024; 23 (01) 46-59
• 21 Basit H, Malik A, Huecker MR. Non-ST-Segment Elevation Myocardial Infarction. StatPearls; 2025
• 22 Akbar H, Foth C, Kahloon RA, Mountfort S. Acute ST-Segment Elevation Myocardial Infarction (STEMI). StatPearls; 2025
• 23 McLaren J, de Alencar JN, Aslanger EK, Meyers HP, Smith SW. From ST-segment elevation MI to occlusion MI: the new paradigm shift in acute myocardial infarction. JACC Adv 2024; 3 (11) 101314
• 24 Kola M, Shuka N, Meyers HP, Zaimi Petrela E, Smith SW. OMI/NOMI: time for a new classification of acute myocardial infarction. J Clin Med 2024; 13 (17) 13
• 25 Spagnolo M, Ammirabile N, Cutore L. et al. Changes in coagulation factor XI activity levels in patients with ST-segment elevation myocardial infarction undergoing primary PCI. Thromb Haemost 2025;
• 26 Loeffen R, van Oerle R, Leers MP. et al. Factor XIa and thrombin generation are elevated in patients with acute coronary syndrome and predict recurrent cardiovascular events. PLoS One 2016; 11 (07) e0158355
• 27 Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342 (10) 696-701
• 28 Greco A, Spagnolo M, Capodanno D. Stent type selection in high bleeding risk patients. Expert Rev Med Devices 2024; 21 (12) 1061-1066
• 29 Agnello F, Mauro MS, Rochira C. et al. PCSK9 inhibitors: current status and emerging frontiers in lipid control. Expert Rev Cardiovasc Ther 2024; 22 (1-3): 41-58
• 30 Valgimigli M, Hong SJ, Gragnano F. et al; Single Versus Dual Antiplatelet Therapy (Sidney-4) Collaborator Group. De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials. Lancet 2024; 404 (10456): 937-948